Introduction {#sec1}
============

Cancer is a notorious disorder that can find loopholes in its basic molecular mechanisms to bypass various signaling pathways, which are hit by small molecule therapeutics. This is one of the ways to evolve toward prolonged survival and metastasis.^[@ref1]^ Cancer chemoresistance is due to the increased expression of P-glycoprotein (Pgp) drug efflux pumps, enhanced drug metabolism, or altered structure of the drug targets.^[@ref2]^ Combination chemotherapy plays a crucial role in cancer treatment due to rising concerns over resistance to single-drug regimen over the course of time.^[@ref3]^ This approach limits the cancer cells to undergo mutational changes needed for cancer cell adaptation and can invoke synergism between the drugs to increase therapeutic efficiency and target selectivity.^[@ref4]^ Due to variations in pharmacokinetics, membrane transport, and biodistribution properties of different chemotherapeutics, dosage and optimization of drug scheduling become highly difficult.^[@ref5]^ Additionally, with more drugs added to the combination module, risks of side effects increase. Nanoengineering can spatially isolate and encapsulate multiple therapeutics at the same time to deliver them simultaneously or sequentially according to various physiological or external stimuli.^[@ref6],[@ref7]^ While codelivery of different single-drug-loaded nanoparticles is possible, importance needs to be given to multidrug-containing particles as they offer vehicle uniformity and ratiometric drug loading with a temporal release of the drugs. There are various reports on multidrug delivery using nanoparticles that showed promise in both in vitro and preclinical stages,^[@ref8],[@ref9]^ liposomes are considered as an ideal drug delivery platform for stimuli-responsive targeted drug delivery applications.^[@ref10]^ So far, several liposomal formulations of drugs such as doxorubicin (Doxil), daunorubicin (DaunoXome), cytarabine (DepoCyt), and vincristine (ONCO-TCS) have been marketed successfully. Due to their vesicular structure, they can load hydrophobic drugs in their unilamellar or multilamellar walls and a hydrophilic drug in their aqueous core. However, poor stability and fragile structure are the major limitations of liposome-based nanoplatforms.^[@ref10],[@ref11]^ Alternatively, polymer-based nanoparticles have been utilized as promising platforms for drug delivery applications due to their predominant stability, low size polydispersity, tunable physicochemical properties, and better loading capacity for poorly water-soluble drugs.^[@ref7],[@ref12]^ Coencapsulation of drugs in polymeric nanoparticles is possible by directly loading water-insoluble molecules in the hydrophobic core, compartmentalizing the core by incorporating a "shell" on the surface for loading a hydrophilic/hydrophobic drug combination, or covalently conjugating different drugs in the polymer chain backbone. A recent work showed the encapsulation of a hydrophobic drug docetaxel in the core with a hydrophilic polymer covalently attached on the surface of doxorubicin.^[@ref13]^ While coencapsulation in the core has little control over the release pattern of the structurally and chemically different drugs, compartmentalized encapsulation provide the option of temporal control with simultaneous or sequential release of the drugs. A recent work validates a compartmentalized drug delivery carrier, where the core is made up of a self-assembled starch-based polymer encapsulating apogossypolone, an anticancer resistance drug, and the shell is decorated with hyaluronic acid nanoparticle loaded with doxorubicin, both associated electrostatically.^[@ref14]^ In another report, hydrophobic combretastatin A4 and the hydrophilic doxorubicin drugs are encapsulated separately in the core and shell of poly(vinylpyrrolidone)/poly(lactic/glycolic acid) (PVP/PLGA) and poly(ε-caprolactone) (PCL)/PLGA nanoparticles.^[@ref15]^ While there are other promising reports in recent years on simple yet effective combinatorial nanomedicines,^[@ref16]−[@ref27]^ it is imperative to fabricate a novel multidrug nanoformulation that can compartmentalize small molecules during a facile synthesis procedure that can be easily scaled up.

The present work explores the pH-dependent surface charge switching carboxymethyl chitosan (CMC)-coated PLGA (cmcPLGA) core--shell nanoparticles encapsulating doxorubicin in the shell and docetaxel in the core prepared using a facile one-pot nanoprecipitation cum self-assembly process. The typical synthesis of cmcPLGA nanoparticle is shown schematically in [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}. The method involves in situ formation of core--shell morphology and compartmentalized docetaxel (Dtxl) and doxorubicin (Dox) loading. The drug loading is driven by hydrophobic interactions between Dtxl and PLGA, while Dox and CMC interact electrostatically. [Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} also clearly shows the encapsulation of Dox in a cmcPLGA core--shell microparticle, which is otherwise difficult to be visualized in the nanoregime.

![Schematic illustration showing fabrication of cmcPLGA core--shell nanoparticles via nanoprecipitation followed by solvent evaporation and electrostatic interaction induced self-assembly process.](ao9b02167_0001){#fig1}

Results and Discussion {#sec2}
======================

Rationale for CarboxyMethyl Chitosan as a Shell {#sec2.1}
-----------------------------------------------

Chitosan in its unmodified form was initially explored to serve as a shell on a PLGA nanoparticle due to its positive charge, and it could enhance cellular uptake due to the charge effect.^[@ref28]^ However, the main purpose of loading a second drug in the shell was not achieved due to a very less doxorubicin encapsulation efficiency of only ∼5%. The main reason could be due to an irregular coating throughout the sample, which is carried out after the PLGA nanoparticle synthesis, causing undesirable nanoparticle aggregation. It was hypothesized that the problem can be solved if the coating is carried out in situ during PLGA nanoprecipitation; yet, chitosan could not be used due to its poor aqueous solubility and the further instability of the PLGA nanodroplets formed if the process was performed in an acidic pH. To address this issue, a water-soluble form of chitosan is required to be used. Carboxymethyl chitosan (CMC) is a well-warranted polymer that has been widely studied because of its ease of synthesis, cost effectiveness, and ampholytic character possessing both cationic (amine) and anionic (carboxyl) functional groups that has made researchers exploring it as a drug delivery carrier and hydrogel in tissue engineering.^[@ref29]^ CMC can be synthesized in various forms predominantly as N,O-CMC or O-CMC, with "O" and "N" representing the hydroxyl substitution and amine substitution with the carboxymethyl group, respectively. The current work needed as many amine groups intact as possible for the electrostatic interaction of CMC with the anionic surface of PLGA nanodroplets during the synthesis process.

Characterization of Carboxymethyl Chitosan {#sec2.2}
------------------------------------------

Prior to nanoparticle preparation, the as-synthesized carboxymethyl chitosan was first characterized using Fourier transform infrared (FTIR) and ^1^H NMR spectroscopy techniques. FTIR spectra shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}A depict peaks at 1080 cm^--1^ corresponding to the glycosidic bond C--O--C and C--O stretching. The peak at 1400 cm^--1^ corresponds to carboxymethyl group, and the peak at 1745 cm^--1^ indicates the carboxyl group. The broad peak at 3455 cm^--1^ is due to the axial stretching of O--H and N--H bonds in chitosan.

![(A) FTIR spectra of chitosan (a), carboxymethyl chitosan (b), and monochloroacetic acid (c). (B) ^1^H NMR spectra of carboxymethyl chitosan (i) and chitosan (ii) with respective structures.](ao9b02167_0002){#fig2}

The ^1^H NMR spectrum of CMC ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}B) in D~2~O at 300 MHz shows a chemical shift at δ1.9, which corresponds to protons of the acetamido group (NHCOCH~3~) in chitosan. Broad resonance between 4 and 4.5 ppm corresponds to protons of O--CH~2~COOD.^[@ref22]^ The appearance of a new signal at 3 ppm corresponds to protons from the NH--CH~2~COOD group between 3 and 3.5 ppm, which means the partial presence of N,O-CMC in the polymer.^[@ref30]^

Morphology and Surface Chemistry of the Shell {#sec2.3}
---------------------------------------------

To evaluate the stability of the blank nanoparticles, dynamic light scattering and ζ-potential measurements were recorded at varying pH values. Due to its ampholytic nature, carboxymethyl chitosan displayed a positive surface charge in the acidic medium owing to the protonation of amine groups and a negative charge at near-neutral and alkaline media due to deprotonation at amine and carboxyl groups. The isoelectric point was found to lie between 5 and 6, with significant particle instability found in this range, as observed from the increased size (600--750 nm) and high polydispersity index (PDI) due to aggregation with ζ-potential values from −3 to +2 mV, as shown in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. This near-neutral charge of the nanoparticles at a pH range of 5.5--6 can significantly influence the preferential adherence due to the partial presence of amine groups followed by accumulation and drug release in an acidic tumor microenvironment.^[@ref31]^

![Hydrodynamic size, polydispersity index (PDI), and ζ-potential of blank cmcPLGA nanoparticles at varying pH conditions. The blue highlighted area shows the pH range where the isoelectric point of the nanoparticles lies.](ao9b02167_0003){#fig3}

Fabrication of Dual-Drug-Loaded Nanoformulations {#sec2.4}
------------------------------------------------

The blank core--shell cmcPLGA nanoparticles synthesized were about 80 nm in size, with a shell width of ∼5 nm as observed by transmission electron microscopy TEM) analysis, as shown in [Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02167/suppl_file/ao9b02167_si_001.pdf). The hydrodynamic size was measured to be about 200 nm. The dual-drug-loaded nanoparticles also showed a core--shell morphology in TEM analysis with a size of ∼100 nm ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}).

![TEM images of Dox--Dtxl (A) and Dtxl (B) loaded cmcPLGA nanoparticles (inset scale bar, 20 nm). Hydrodynamic diameter, intensity-weighted size distribution, and ζ-potential measurements of single- and dual-drug formulations.](ao9b02167_0004){#fig4}

Drug loading significantly affected the PLGA nanoparticle size when compared to that of blank nanoparticles, as shown in [Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02167/suppl_file/ao9b02167_si_001.pdf). Among three different drugs analyzed for encasing in the core, docetaxel showed better encapsulation (∼94%) compared to that of tamoxifen citrate (∼15%) and doxorubicin (∼17.5%) due to its proven hydrophobic interaction with PLGA.^[@ref32]^ Doxorubicin, when loaded into the shell, caused a reduction in the hydrodynamic size and ζ-potential of the final core--shell nanoparticle at pH 7.4, from 250 to 200 nm and −16.7 to −8.88 mV, respectively ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}). A simultaneous reduction in size and ζ-potential in the presence of Dox could be related to the compaction effect provided by the Dox-CMC shell and the positively charged Dox, masking the negative carboxyl groups of CMC. The charge masking effect of Dox is in line with a previous report, which showed conjugation of the drug with hyaluronic acid, flipping the surface charge from negative to positive.^[@ref14]^ Size reduction also decreased the encapsulation efficiency of Dtxl to ∼65% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}) in the presence of Dox.

###### Dual-Drug Encapsulation and Loading Efficiency

                encapsulation efficiency (%)   loading content (%)                 
  ------------- ------------------------------ --------------------- ------------- -------------
  Dox F         55 ± 25.1                                            1.62 ± 0.01    
  Dtxl F                                       94 ± 15.3                           3.28 ± 0.13
  Dox--Dtxl F   50 ± 9.2                       65 ± 12.08            1.2 ± 0.03    2.06 ± 0.09

While a previous work has reported Dox-loaded CMC nanoparticles for nanodrug delivery,^[@ref33]^ in the present work it is vital to optimize the CMC concentration at which better Dox loading is possible in the shell of the nanoparticles. An increase in Dox encapsulation (∼55%) with the increase in CMC concentration up to 0.25% w/v was observed, beyond which the nanoparticle yield reduced drastically, adversely affecting the drug loading as can be seen in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}.

![Percent Dox encapsulation under different CMC concentrations (A) (inset, UV--visible spectra of Dox extracted from the nanoparticles prepared with different weight percentages of CMC). Percent Dox loading with and without the CMC coating (B).](ao9b02167_0005){#fig5}

A higher Dox loading was noted in the presence of CMC (∼1.2% with Dtxl and ∼1.6% without Dtxl) compared to the Dox loading in the absence of CMC (∼0.5% with Dtxl and ∼0.7% without Dtxl), as shown in [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}B, due to the electrostatic interaction of more Dox molecules with CMC. Dox loading seen in the absence of CMC is due to its interaction with carboxyl and hydrophobic functional groups in the superficial layers of PLGA that can also occur in the presence of CMC, aiding better loading.

Drug Release Kinetics {#sec2.5}
---------------------

A sequential drug release was observed with a faster Dox release than Dtxl owing to its presence in the shell with a lesser resistance from CMC, smaller distance to diffuse out, and hydrophilicity that help in moving toward the aqueous medium at pH 7.4. Both the drugs showed a biphasic release pattern with a burst within the first hour followed by a short saturation with a lagged release till sixth hour after which it reached a steady state ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). The second saturation was not observed in the case of Dtxl when loaded as a single drug in the nanoparticles, possibly due to the absence of resistance from the electrostatically cross-linked Dox-CMC shell. This resistance is also expected to limit the overall release of both the drugs in the dual-drug formulation under normal physiological conditions. The presence of ∼80% of Dtxl and ∼55% of Dox in the nanoparticle at the end of 24 h provides for the release of the remaining cargo after being uptaken by the cancer cells.

![Drug release pattern from single- and dual-drug-loaded cmcPLGA nanoparticles.](ao9b02167_0006){#fig6}

Engineered Nanoformulation for Cancer Cell Growth Inhibition {#sec2.6}
------------------------------------------------------------

The effect of single- and dual-drug formulations was assessed in three different cell lines, viz., BT549 (breast ductal carcinoma), PC3 (prostate cancer), and A549 (lung adenocarcinoma), each being different in their tissue of origin. These cell lines were selected to observe the toxicity of formulation on the basis of the proliferation index of the cells. Both cancer cell lines BT549 and PC3 are indicated in opposite sexes, female and male, respectively, with closer proliferation indexes of 2.3 and 2.1.^[@ref34],[@ref35]^ The A549 cancer cells are indicated as common for both sexes with a proliferation index of 1.1,^[@ref36]^ which is about half of the other two cell lines. The dual-drug formulation was found to carry ∼1.7:1 weight ratio of Dtxl/Dox at the optimized conditions nanoengineered for a sequential release of Dox followed by Dtxl. The clinically correlated ratio ranges from 1.2:1 to 1.5:1, depending upon study objectives with sequential administration of Dox followed by Dtxl in metastatic breast cancer patients.^[@ref37],[@ref38]^ The core--shell nanoparticles showed time-dependant uptake in cancer cells with significant accumulation in the cytoplasm at the end of 6 h incubation ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02167/suppl_file/ao9b02167_si_001.pdf)). The free drug response at end of 48 h incubation was found to differ for each of the cell lines with BT459 requiring a maximum free Dox concentration of about 1.934 μg/mL (3.56 μM) to reach IC50 ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}) followed by PC3 (1.812 μg/mL; 3.33 μM) and A549 (0.253 μg/mL; 0.465 μM). In the case of free Dtxl, A549 showed a cytostatic effect scoring the maximum IC50 of 5.716 μg/mL (7.09 μM) followed by a dose-dependent growth inhibitory effect for both BT549 and PC3 with IC50 values of 1.15 and 0.266 μM, respectively. Nanoformulations showed better growth inhibition compared to that of free drug formulations. While single-drug nanoformulation had a prominent effect at higher concentrations, dual-drug nanoformulation showed significant cell growth inhibition even at lower drug concentrations, mainly due to their synergistic effect ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}). The IC50 values of the dual-drug formulation were found to be as low as 5 ng/mL (Dox equivalent, 9.2 nM) and 7 ng/mL (Dtxl equivalent, 8.68 nM) in A549 cell line. As expected, the IC50 values were higher in BT549 (Dox equivalent, 44.23 nM and Dtxl equivalent, 62 nM) and PC3 (Dox equivalent, 22 nM and Dtxl equivalent, 33.5 nM) cells owing to their high proliferation index. The combination Index that predicts whether a two-drug therapeutic regime follows synergism (C.I. \< 1), additive (C.I. = 1), or antagonism (C.I. \> 1) showed synergism in the case of Dox--Dtxl cmcPLGA nanoparticles with values between 0.2 and 0.3 for all of the three cell lines ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). A comparative chart of Dox and Dtxl IC50 values in the three cell lines with the previously reported values is tabulated in [Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02167/suppl_file/ao9b02167_si_001.pdf).

![Dual-drug cell inhibitory effect of dual-drug-loaded cmcPLGA nanoparticles (e) on BT549, PC3, and A549 cancer cell lines as compared with that of free drug (a, Dox; b, Dtxl) and single-drug (c, Dox-cmcPLGA; d, Dtxl cmcPLGA) formulations at 48 h. \*Two-tailed p value \<0.01.](ao9b02167_0007){#fig7}

###### IC50 Values (ng/mL) of Single- and Dual-Drug Formulations for Three Different Cancer Cell Lines

                                                             Dtxl--Dox formulation             
  --------- ------------ ------------ ---------- ----------- ----------------------- --------- ------
  A549      253 ± 6      5716 ± 597   134 ± 14   236 ± 16    5 ± 3                   7 ± 5     0.27
  BT459     1934 ± 78    928 ± 45     264 ± 19   349 ± 107   24 ± 10                 50 ± 21   0.24
  **PC3**   1812 ± 197   215 ± 6      917 ± 82   204 ± 20    12 ± 3                  27 ± 10   0.2

Acridine orange and Ethidium bromide (AO/EtBr) Staining and Cell Cycle Analysis {#sec2.7}
-------------------------------------------------------------------------------

Acridine orange and ethidium bromide (AO/EtBr) staining of PC3 prostate cancer cells showed chromatin breakdown, as can be seen in [Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}, a characteristic feature of apoptosis, and it was prominent in cells treated with the dual-drug formulation (Dox, 50 ng/mL; Dtxl, 100 ng/mL) than cells treated with free and single-drug formulations, each at a concentration of 100 ng/mL. Our results clearly showed that Dox augmented the cytotoxic effects of Dtxl, which was further validated by cell cycle analysis. Dtxl and Dox are known to inhibit the cell cycle at the G2/M phase.^[@ref39],[@ref40]^ Dox--Dtxl combination formulation profoundly (\>80%) inhibited the cells at the G2/M phase compared to single-drug formulations ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}).

![Determination of morophlogical changes by acridine orange/ethidium bromide staining. (I) Untreated, (II) Dox 100 ng/mL, (III) Dtxl 100 ng/mL, (IV) Dox formulation 100 ng/mL, (V) Dtxl formulation 100 ng/mL, and (VI) Dox--Dtxl formulation 50--100 ng/mL treated PC3 cells for 24 h showing various degrees of apoptotic chromatin breakdown.](ao9b02167_0008){#fig8}

![Flow cytometric analyses of PC3 cells treated with free Dox (100 ng/mL), free Dtxl (100 ng/mL), Dox formulation (100 ng/mL), Dtxl formulation (100 ng/mL), and Dox--Dtxl formulation (50--100 ng/mL) for 24 h.](ao9b02167_0009){#fig9}

Conclusions {#sec3}
===========

We report nanoparticles made of a PLGA core and a carboxymethyl chitosan shell with a pH-specific change in surface charge and compartmentalized dual-drug loading using a one-pot synthesis procedure. Nanoparticle characterization showed visible CMC coating with Dtxl (core) and Dox (shell) encapsulation of 94 and 55%, respectively. Due to the polyampholytic nature of CMC, the synthesized core--shell nanoparticles were found to have a positive and negative surface charge at acidic and alkaline pH values, respectively, with the isoelectric point lying between pH values of 5 and 6. The drug release profile showed a sequential release of Dox followed by Dtxl at physiological pH (7.4). The cell growth inhibitory effect of dual-drug formulation was significantly higher than that of free drug and single-drug nanoformulations. The combination drug delivery showed synergism between the two drugs, thus proving efficient than the control groups. While herein we report a combinatorial nanomedicine, the potential of the technology to fabricate layered microparticles to serve as postsurgical local implants for controlled sequential drug delivery cannot be ruled out. In both cases, a comprehensive in vivo study would fetch more light to establish the efficiency of the combination drug delivery in preclinical tumor models.

Experimental Section {#sec4}
====================

Chemicals and Reagents {#sec4.1}
----------------------

Chitosan (medium molecular weight), docetaxel, doxorubicin hydrochloride, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), acridine orange, propidium iodide, and ethidium bromide were purchased from Sigma-Aldrich Ltd. PLGA (17 kDa, 50:50) was provided by PURAC Biomaterials. Monocloroacetic acid and polyvinyl alcohol were purchased from S.D. Fine Chemicals Ltd. RNAse A was purchased from Invitrogen. Cell lines PC3 and A549 were procured from NCCS, and BT549 was a gift sample from CCMB. Dialysis membrane, fetal bovine serum (FBS), DMEM, RPMI1640, penicillin--streptavidin solution, and trypsin EDTA were purchased from HiMedia Ltd. All solvents used were of analytical grade.

Synthesis of CarboxyMethyl Chitosan {#sec4.2}
-----------------------------------

The synthesis of CMC was as per protocol reported by Zhu et al.^[@ref29]^ Chitosan (8% w/v) was immersed in 25 mL of NaOH (50% w/v) solution to swell for 24 h. The alkalized chitosan was crushed into a filtration cake and then transferred into a flask. Five grams of monochloroacetic acid was dissolved in 25 mL of isopropanol and then added to the flask dropwise for 20 min. The reaction in the flask was allowed to continue for 8 h at room temperature, after which the mixture was filtered to remove the solvent. The filtrate obtained was dissolved in 100 mL of water, and 2.5 M HCl was added to it to adjust its pH to ∼7. Following pH adjustments, anhydrous ethanol was added to precipitate the product that is further centrifuged to remove the precipitate. Finally, the product was filtered, rinsed thrice with anhydrous ethanol, and vacuum-dried at room temperature.

Synthesis of Dual-Drug loaded Carboxymethyl chitosan-Coated PLGA (cmcPLGA) Nanoparticles {#sec4.3}
----------------------------------------------------------------------------------------

The core--shell nanoparticles was prepared using a single-step nanoprecipitation self-assembly process by slowly adding 5 mL of organic phase (tetrahydrofuran) containing 5 mg/mL PLGA (17 kDa, 50:50) and docetaxel (10% w/w of PLGA) into 10 mL of aqueous mixture containing previously synthesized carboxymethyl chitosan (0.25% w/v), doxorubicin hydrochloride (10% w/w of CMC), and PVA (2% w/v) under vigorous stirring followed by solvent evaporation at room temperature. After complete solvent evaporation, the nanoparticles were separated from excess PVA by centrifugation at 15 000 rpm for 30 min and further washed once with double distilled water at 15 000 rpm for 10 min. The nanoparticles were dispersed in double distilled water at 1 mg/mL concentration prior to freeze-drying and stored at 4 °C until further use.

Drug Encapsulation and Loading Studies {#sec4.4}
--------------------------------------

A known quantity of Dox--Dtxl-loaded nanoparticles were dispersed in water--acetonitrile mixture and left for drug dissolution into the solution phase under constant shaking overnight. The mixture was centrifuged to remove polymer debris, and the supernatant was analyzed using high-performance liquid chromatography (HPLC) for doxorubicin and docetaxel absorbance at λ~max~ of 230 nm with retention times of 6.06 and 7.118 min, respectively ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02167/suppl_file/ao9b02167_si_001.pdf)). This method was used to directly measure the amount of the drug loaded in the particles. The EE (encapsulation efficiency) and LC (loading content) of drugs were calculated using the following formulas

Drug Release Study {#sec4.5}
------------------

The dual-drug release study from cmcPLGA nanoparticles was performed by a dialysis membrane method for the samples against 1% Tween 80 in phosphate-buffered saline (pH 7.4) at 37 °C. Predetermined quantities of aliquots were taken from the release medium at regular time intervals and replaced with an equal volume of fresh buffer to maintain constant sink conditions. The aliquots were quantified for both docetaxel and doxorubicin using HPLC as mentioned earlier. The measurements were performed in triplicate for calculating mean ± standard deviation.

Cell Growth Inhibition Studies {#sec4.6}
------------------------------

To elucidate the effect of unloaded and Dox--Dtxl-loaded cmcPLGA nanoparticles on cancer cells, the MTT assay was performed according to the method reported by Mallavadhani et al.^[@ref41]^ A549 and PC3 cells were cultured in RPMI1640, and BT549 cells were cultured in DMEM. Culture media were supplemented with 10% fetal bovine serum, penicillin, and streptomycin. Briefly, A549, PC3, and BT549 cells were seeded at a density of 1 × 10^4^ cells per well in a 96-well plate containing 10% FBS. After 24 h, cells were treated with different concentrations of free drug, dual-drug, and single-drug nanoformulations for a period of 48 h. At the end of incubation, 10 μL of MTT (5 mg/mL) in 100 μL medium was added and incubated at 37 °C for 4 h. Then, the media with MTT was removed and the purple formazan crystals formed were dissolved in 200 μL of dimethyl sulphoxide and read at 570 nm using a multidetection plate reader (SpectraMax M4, Molecular Devices, USA). The cell inhibitory efficiency and dual-drug combination index were calculated as followswhere A~sample~ and A~control~ are absorbance values of nanoparticle-treated and untreated cells, respectively.where D~1~ and D~2~ are drug concentration of Dox and Dtxl, respectively, and D~50a~ and D~50b~ are 50% inhibitory concentration (IC50) values of Dox formulation and Dtxl formulation, respectively.

Acridine orange and Ethidium bromide (AO/EtBr) {#sec4.7}
----------------------------------------------

AO/EtBr staining was performed for imaging apoptotic chromatin breakdown in treated cells according to the method reported by Mallavadhani et al.^[@ref41]^ PC3 cells were grown in 6-well plates for 24 h followed by treatment with the samples for 24 h. After the incubation period, the cells were fixed with 1% glutaraldehyde for 30 min and observed under a inverted fluorescence microscope with the help of a digital camera (Nikon, Inc. 246 Japan) at 200X magnification.

Cell Cycle Analysis {#sec4.8}
-------------------

To determine the effect of Dox, Dtxl, and Dox--Dtxl formulations on cell cycle analysis, 24 h after plating 1 × 10^6^ PC3 cells on 6-well plates, cells were incubated with free drug, single, and combination formulations for 24 h. Thereafter, cells were washed in phosphate-buffered saline, trypsinzed, and fixed in 70% alcohol. After fixing, RNAse A (1 mg/mL) and PI (10 mg/mL) were added to each sample. Samples were incubated at room temperature in complete darkness for 30 min. Cell cycle distribution was determined using BD fluorescence-activated cell sorting (FACS) verse. The results were analyzed by BD FACSuite software.

Statistical Analysis {#sec4.9}
--------------------

An unpaired student's *t*-test (two-tailed) with confidence intervals of 99% and 95% was taken for analysis using Graph Pad software. The groups compared are indicated as necessary.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.9b02167](http://pubs.acs.org/doi/abs/10.1021/acsomega.9b02167).Nanoparticle characterization methods; HPLC chromatogram of doxorubicin and docetaxel; scanning electron microscopy images of blank nanoparticles; nanoparticle cellular uptake; and tabulation of doxorubicin and docetaxel IC50 values ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.9b02167/suppl_file/ao9b02167_si_001.pdf))
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